684 results match your criteria: "Claude Bernard University Lyon[Affiliation]"
J Fungi (Basel)
June 2023
UR3738 Centre pour l'lnnovation en Cancérologie de Lyon, Team Inflammation and Immunity of the Respiratory Epithelium, Claude Bernard University-Lyon 1, 69495 Pierre Bénite, France.
Cytokine
September 2023
Hospices Civils de Lyon, Immunology Laboratory, Hôpital E. Herriot, Lyon France; Université de Lyon, EA 7426 "Pathophysiology of Injury-Induced Immunosuppression", Université Claude Bernard Lyon_1, Lyon, France. Electronic address:
In sepsis, personalized immunotherapy is being evaluated as a means of restoring immune function in the most severely affected patients. Biomarkers play a crucial role in this process, as there are no clear clinical indicators of immune dysfunction. Functional testing is considered a gold standard for assessing immune function, but this approach faces analytical challenges in terms of clinical implementation.
View Article and Find Full Text PDFInjury
September 2023
Université Claude Bernard Lyon 1, Centre Lyonnais d'Enseignement par la Simulation en Santé (CLESS), Lyon, France; Service d'Anesthésie-Réanimation, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France; Service de Médecine Intensive Adulte, Centre Hospitalier Universitaire Vaudois, 1011 Lausanne, Suisse.
Front Med (Lausanne)
May 2023
Department of Hematology and Oncology, University Medical Center, Mainz, Germany.
Introduction: CAR T-cell therapy has emerged as a promising new immuno-oncology treatment that engages the patient's immune system to fight certain hematological malignancies, including diffuse large B-cell lymphoma (DLBCL). In the European Union (EU), CAR T-cell therapies have been approved for relapsed/refractory (R/R) DLBCL patients since 2018, but patient access is often still limited or delayed. This paper is aimed at discussing challenges to access and possible solutions in the largest four EU countries.
View Article and Find Full Text PDFRMD Open
June 2023
Immunology Laboratory, Hôpital Lyon-Sud, Hospices Civils de Lyon, Lyon, France
An European Alliance of Associations for Rheumatology task force recently recommended specific points to consider for exploring type I interferon pathway in patients, highlighting the lack of analytical assays validated for clinical routine. We report here the French experience on a type I interferon pathway assay that has been set up and used routinely since 2018 in Lyon, France.
View Article and Find Full Text PDFMod Pathol
October 2023
Institute Bergonié, Department of Biopathology, Comprehensive Cancer Center, Bordeaux, France; INSERM Unit 1312, Bordeaux, France. Electronic address:
Contrib Nephrol
August 2023
Anesthesiology and Intensive Care Medicine, Edouard Herriot Hospital, Hospices Civils de Lyon, Lyon, France,
Patients with severe thermal injury require urgent specialized care in burn units. These units assure good coordination of a bundle of care including fluid resuscitation, nutritional support, respiratory care, surgical care and wound care, infection prevention, and rehabilitation. When severely injured, burn patients present a systemic inflammatory response syndrome, associated with a dysregulated immune homeostasis.
View Article and Find Full Text PDFFront Oncol
May 2023
Univ Lyon, Université Claude Bernard Lyon 1, Centre National de la Recherche Scientifique (CNRS), LAGEPP Unité Mixte de Recherche (UMR) 5007, Villeurbanne, France.
Peritoneal carcinomatosis (PC) is a common outcome of epithelial ovarian carcinoma and is the leading cause of death for these patients. Tumor location, extent, peculiarities of the microenvironment, and the development of drug resistance are the main challenges that need to be addressed to improve therapeutic outcome. The development of new procedures such as HIPEC (Hyperthermic Intraperitoneal Chemotherapy) and PIPAC (Pressurized Intraperitoneal Aerosol Chemotherapy) have enabled locoregional delivery of chemotherapeutics, while the increasingly efficient design and development of advanced drug delivery micro and nanosystems are helping to promote tumor targeting and penetration and to reduce the side effects associated with systemic chemotherapy administration.
View Article and Find Full Text PDFJ Proteome Res
July 2023
Department of Biochemistry and Molecular Genetics, University of Colorado Denver─Anschutz Medical Campus, Aurora, Colorado 80045, United States.
Epidemiological data predicts that sub-Saharan Africa will have the largest increase in type 2 diabetes (T2D) prevalence over the next two decades. Metabolomics studies have identified biomarkers that could improve T2D diagnosis and follow-up. However, no studies have characterized the metabolome of people from sub-Saharan Africa.
View Article and Find Full Text PDFEur Respir J
July 2023
Department of Medicine, University of British Columbia, Vancouver, BC, Canada.
Interstitial lung disease (ILD) is a diverse group of inflammatory and fibrotic lung conditions causing significant morbidity and mortality. A multitude of factors beyond the lungs influence symptoms, health-related quality of life, disease progression and survival in patients with ILD. Despite an increasing emphasis on multidisciplinary management in ILD, the absence of a framework for assessment and delivery of comprehensive patient care poses challenges in clinical practice.
View Article and Find Full Text PDFEuro Surveill
June 2023
Direction des maladies infectieuses, Santé Publique France, Saint-Maurice, France.
Cytometry B Clin Cytom
November 2023
Hospices Civils de Lyon, Immunology Laboratory, Hôpital E. Herriot, Lyon, France.
Int J Gynaecol Obstet
October 2023
Department of Gynecologic Oncology, Hadassah Medical Organization and Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
Objective: We aim to study gender representation among the different national gynecologic oncology (GO) societies' presidents over the past decade.
Methods: A cross-sectional study examining the period 2013-2022. The leadership positions in 11 GO societies in the USA (SGO), internationally (IGCS), Europe (ESGO), Australia (ASGO), Israel (ISGO), Japan (JSGO), Asia-Oceania (AOGIN), India (INSGO), Latin America (SLAGO), South Africa (SASGO), and Turkey (TRSGO) was studied.
Clin Chim Acta
June 2023
Department of Pharmacology and Toxicology, Raymond Poincaré hospital, GHU AP-HP.Paris-Saclay, 92380 Garches, France; Paris-Saclay University, UVSQ, Inserm U-1018, Centre de Recherche en Épidémiologie et Santé des Populations (CESP), Team MOODS & Plateform MasSpecLab, 78180 Montigny-le-Bretonneux, France.
Geriatr Psychol Neuropsychiatr Vieil
May 2023
Service d'audiologie et d'explorations otoneurologiques, CHU de Lyon, Hôpital Édouard-Herriot, Lyon, France, Claude-Bernard University Lyon 1, Institut de l'audition, Institut Pasteur, Inserm, Paris, France.
Introduction: Presbycusis is the physiological decrease in hearing due to advancing age and begins well before the sixth decade. These recommendations recall the principles of early diagnosis of presbycusis and the means of optimal rehabilitation as soon as the first symptoms appear.
Material And Methods: The recommendations are based on a systematic analysis of the literature carried out by a multidisciplinary group of ENT physicians, audiologists, geriatricians and hearing specialists from all over France.
Nat Rev Rheumatol
June 2023
Nephrology and Dialysis Unit, Meyer Children's Hospital IRCCS, Florence, Italy.
Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, characterized by asthma, eosinophilia and granulomatous or vasculitic involvement of several organs. The diagnosis and management of EGPA are often challenging and require an integrated, multidisciplinary approach. Current practice relies on recommendations and guidelines addressing the management of ANCA-associated vasculitis and not specifically developed for EGPA.
View Article and Find Full Text PDFJAMA
May 2023
Centre for Interstitial Lung Diseases and Sarcoidosis, Department of Respiratory Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.
Importance: There is a major need for effective, well-tolerated treatments for idiopathic pulmonary fibrosis (IPF).
Objective: To assess the efficacy and safety of the autotaxin inhibitor ziritaxestat in patients with IPF.
Design, Setting, And Participants: The 2 identically designed, phase 3, randomized clinical trials, ISABELA 1 and ISABELA 2, were conducted in Africa, Asia-Pacific region, Europe, Latin America, the Middle East, and North America (26 countries).
J Clin Med
April 2023
Nephrology, Rheumatology and Dermatology Unit, National Reference Centre for Rare Rheumatic Autoimmune and Systemic Diseases in Children (RAISE), Mère Enfant Hospital, Hospices Civils de Lyon, 69500 Bron, France.
Introduction: Biological disease-modifying anti-rheumatic drugs (bDMARDs) targeting interleukin (IL)-6 and IL-1β represent a steroid-sparing first-line therapy used in systemic-onset juvenile idiopathic arthritis (sJIA). Recently, the occurrence of pulmonary alveolar proteinosis (PAP) in sJIA patients was reported with early-onset and exposure to bDMARDs as potential risk factors. We report on a new case with longitudinal immunomonitoring successfully treated by Janus Kinase inhibitors (JAKi) and review past clinical descriptions of this new entity.
View Article and Find Full Text PDFCirc Genom Precis Med
June 2023
Laboratoire de Cardiogénétique Moléculaire (A.J., G.M.), Hospices Civils de Lyon, Lyon, France.
Urology
June 2023
Department of Urology, Lyon Sud ... Hospices Civils de Lyon, Lyon, France.
Objective: To analyze surgical and functional outcomes of bilateral pedicled scrotal flaps for penile shaft reconstruction.
Materials And Methods: A retrospective analysis was performed on 22 patients who underwent penile shaft reconstruction with bilateral pedicled scrotal flaps between 2009 and 2017. Demographics, peri-operative data, and surgical complications were collected.
Kidney Int
June 2023
CHU Nantes, Nantes Université, INSERM, Center for Research in Transplantation and Translational Immunology (CR2TI), UMR 1064, ITUN, Nantes, France; Centre d'Investigation Clinique en Biothérapie, Centre de Ressources Biologiques (CRB), CHU Nantes, Nantes, France; LabEx IGO "Immunotherapy, Graft, Oncology", Nantes Université, Nantes, France. Electronic address:
We previously established a six-gene-based blood score associated with operational tolerance in kidney transplantation which was decreased in patients developing anti-HLA donor-specific antibodies (DSA). Herein, we aimed to confirm that this score is associated with immunological events and risk of rejection. We measured this using quantitative PCR (qPCR) and NanoString methods from an independent multicenter cohort of 588 kidney transplant recipients with paired blood samples and biopsies at one year after transplantation validating its association with pre-existing and de novo DSA.
View Article and Find Full Text PDFJ Immunol
May 2023
CIRI, Centre International de Recherche en Infectiologie, (Team LYACTS), Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, Lyon, France.
Pediatr Rheumatol Online J
March 2023
Research on Healthcare Performance (RESHAPE), INSERM U1290, Claude Bernard University Lyon 1, Lyon, France.
Background: Despite guidelines, poor access to appropriate care for juvenile idiopathic arthritis (JIA) patients remains a global issue. Prompt referral to a pediatric rheumatology (PR) center and effective care is known to be critical for changing the natural history of the disease and improving long-term prognosis. This project assesses socio-economic factors of delayed referral to a pediatric rheumatologist (PRst) for JIA patients in France and Switzerland within the Juvenile Inflammatory Rheumatism (JIR) Cohort.
View Article and Find Full Text PDFCancers (Basel)
March 2023
Institut of Pharmaceutical and Biological Sciences (ISPB), Claude Bernard Lyon I, 69373 Lyon, France.
Introduction: Progressive advanced non-small cell lung cancer (NSCLC) accounts for about 80-85% of all lung cancers. Approximately 10-50% of patients with NSCLC harbor targetable activating mutations, such as in-frame deletions in Exon 19 (Ex19del) of . Currently, for patients with advanced NSCLC, testing for sensitizing mutations in is mandatory prior to the administration of tyrosine kinase inhibitors.
View Article and Find Full Text PDFInt J Lab Hematol
June 2023
Research Haematology Department, University College London, London, UK.
This guideline has been written on behalf of the International Council for Standardisation in Haematology (ICSH) and focuses on two point of care haematology tests used within primary care, namely International Normalised Ratio (INR) and D-dimer. Primary care covers out of hospital settings and can include General Practice (GP), Pharmacy and other non-hospital settings (although these guidelines would also be applicable to hospital out-patient settings). The recommendations are based on published data in peer reviewed literature and expert opinion; they should supplement regional requirements, regulations or standards.
View Article and Find Full Text PDF